QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moretti, M. E Articles by Koren, G. Search for Related Content PubMed PubMed Citation Articles by Moretti, M. E Articles by Koren, G.

Breast-Feeding During Maternal Use of Azathioprine

Assistant Director, The Motherisk Program and Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada

Zul Verjee, PhD

Biochemist, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto

Shinya Ito, MD

Director, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children; Professor, Department of Pediatrics, University of Toronto, Toronto

Gideon Koren, MD

Director, The Motherisk Program, The Hospital for Sick Children; Professor, Department of Pediatrics, University of Toronto; Ivey Chair in Molecular Toxicology, Department of Medicine, The University of Western Ontario, London, ON

Reprints: Ms. Moretti, Division of Clinical Pharmacology and Toxicology, The Motherisk Program and The Hospital for Sick Children, 555 University Ave., Toronto, ON M5G 1X8, Canada, fax 416/813-7562, momrisk{at}sickkids.ca

OBJECTIVE: To report the clinical outcome of infants whose mothers were taking azathioprine while nursing and to quantify the transfer of 6-mercaptopurine (6-MP), its active metabolite, into breast milk.

CASE SUMMARY: We report on a series of 4 patients treated with azathioprine while lactating. Breast milk samples were analyzed for 6-MP in 2 of the mothers. Several milk samples per patient were analyzed; levels of 6-MP were undetectable by high performance liquid chromatography (limit of detection 5 ng/mL). Therefore, the absolute relative infant dose would have been less than 0.09% of the maternal weight-adjusted dose. No adverse effects were encountered in any of the 4 infants.

DISCUSSION: A large number of women of reproductive age are treated with azathioprine for a range of chronic conditions that require immunosuppression, such as systemic lupus erythematosus or solid organ transplants. Similar to other antimetabolites, the drug has generally been contraindicated for use during breast-feeding because of the theoretical concern for toxicity in the nursing infant. The available literature in this area is sparse and dated. The data presented here confirm published reports of minimal 6-MP excretion into milk, suggesting that significant systemic adverse effects in the infant are unlikely.

CONCLUSIONS: Maternal azathioprine use during lactation does not appear to pose a significant immediate clinical risk to the suckling infant. Continued monitoring and long-term assessment of these infants are warranted.

Key Words: azathioprine, breast-feeding, lactation, 6-mercaptopurine

Published Online, November 28, 2006. www.theannals.com, DOI 10.1345/aph.1H152

This article has been cited by other articles:

				S. J Gardiner, R. B Gearry, R. L Roberts, M. Zhang, M. L Barclay, and E. J Begg Comment: Breast-feeding During Maternal Use of Azathioprine Ann. Pharmacother., April 1, 2007; 41(4): 719 - 720. [Full Text] [PDF]

				M. E Moretti, Z. Verjee, S. Ito, and G. Koren Authors' Reply Ann. Pharmacother., April 1, 2007; 41(4): 720 - 720. [Full Text] [PDF]